Xiaoling Xu

Chemotherapy remains effective in ALK-TKI therapy: a retrospective analysis in ALK-positive advanced NSCLC

Tyrosine kinase inhibitors (TKIs) are the standard therapy for advanced non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) fusions. However, acquired resistance remains a major challenge, necessitating strategies to prolong therapeutic efficacy. This st...